AIM
AXDX

Artemis Investment Management’s Accelerate Diagnostics AXDX Stock Holding History

Artemis Investment Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-10,011
Closed -$2.25M – 224
2017
Q3 		$2.25M Buy
+10,011
New +$2.46M 0.05% 191

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Artemis Investment Management's AXDX Position: Q4 2017 in Review

Artemis Investment Management sold out of Accelerate Diagnostics (AXDX) in Q4 2017, closing a stake of 10,011 shares — an estimated $2.25M sold.

Artemis Investment Management first reported a position in AXDX in Q3 2017 and held it in 1 quarter. The position peaked at $2.25M in Q3 2017. 117 funds tracked by Wall St. Rank hold AXDX as of Q4 2017.

  • Artemis Investment Management reported no remaining Accelerate Diagnostics position as of Q4 2017 after selling out during the quarter.
  • Artemis Investment Management sold 10,011 Accelerate Diagnostics shares in Q4 2017, an estimated $2.25M.
  • Artemis Investment Management first reported a position in Accelerate Diagnostics in Q3 2017 and held it in 1 quarter.
  • Artemis Investment Management's Accelerate Diagnostics position peaked at $2.25M in Q3 2017.
  • 117 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2017.

Based on Artemis Investment Management's 13F filing for Q4 2017, filed 8 Feb 2018.